Alzheimers disease Alzheimers disease
Conditions
Interventions
None listed
Sponsors
Takeshi Iwatsubo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who receive Disease-Modifying Treatments for Alzheimer's disease based on the Optimal Use Promotion Guidelines. Patients who have indicated their own free will to participate in this study. (In situations where patients are deemed unable to provide written consent, a representative, such as a family member, should obtain the written consent.)
Exclusion criteria
Exclusion criteria: Patients who declared for rejection of participating this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relation between the frequency and onset time of ARIA-E and ARIA-H, and the APOE genotype | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Clinical Dementia Rating sum of boxes (CDR) 2. Mini-Mental State Examination (MMSE) 3. Lawton or Functional Activities Questionnaire (FAQ) 4. Caregiving information 5. Changes in plasma biomarkers over time 6. Frequency and timing of infusion reactions as side effects | — |
Contacts
Public ContactIwatsubo Takeshi
National Center of Neurology and Psychiatry
Outcome results
None listed